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ReviewPlasmacytoid dendritic cells (PDCs) represent a subset of
circulating leukocytes characterized by the ability to
release high levels of type I interferon (IFN). Under
homeostatic conditions PDCs are confined to primary
and secondary lymphoid organs. This is consistent
with the restricted profile of functional chemotactic
receptors expressed by circulating PDCs (i.e. CXCR4
and ChemR23). Accumulation of PDCs in non-lymphoid
tissue is, however, observed in certain autoimmune
diseases, allergic reactions and tumors. Indeed, PDCs
are now considered to be involved in the pathogenesis of
diseases characterized by a type I IFN-signature and are
considered as a promising target for new intervention
strategies. Here, current knowledge of the molecular
mechanisms involved in the recruitment of PDCs
under homeostatic and pathological conditions are
summarized.
Background on PDCs: history and function
The cell now recognized as a plasmacytoid dendritic cell
(PDCs) was originally described as a ‘‘lymphoblast’’ on the
basis of its morphological features. It was subsequently
renamed ‘‘T-associated plasma cell’’ due to the abundance
of rough endoplasmic reticulum, ‘‘plasmacytoid T cell’’ by
reason of CD4 expression, and ‘‘plasmacytoid monocyte’’
for the expression of some myelo-monocytic markers in the
absence of B- and T-cell specific antigens [1]. The function
of PDCs remained completely unknown until it was
reported that PDCs represent a subset of dendritic cells
(DCs) [2], and that they correspond to the natural type I
interferon (IFN)-producing cells [3,4].
PDCs originate in the bone marrow, from both myeloid
and lymphoid precursors, although myeloid derivation is
predominant, where a dendritic cell (DCs) progenitor gives
rise to PDCs and classical ‘‘myeloid’’ DCs (MDCs) [5,6].
PDCs can differentiate into MDCs after stimulation and
genome-wide analysis showed that the gene expression
profile of PDCs is closer to MDCs than to other hemato-
poietic cells [7,8]. The development of both PDCs and
MDCs depends on Fms-like kinase 3 ligand (Flt3L), but
the E2-2 transcription factor is uniquely required for PDCs
differentiation [9,10].
Peripheral human PDCs have a unique cell surface
phenotype: they lack B cell, T cell, myeloid cell, and NKCorresponding author: Sozzani, S. (sozzani@med.unibs.it).
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CD303 (BDCA2), ILT3 and ILT7 [9]. Among these mol-
ecules, BDCA2 and ILT7 are highly specific for PDCs.
These cell surface receptors use the transmembrane
adaptor protein FceRIg chain, inhibit type I IFN and PDCs
inflammatory chemokine production upon engagement by
antibodies or ligands, and are down-regulated upon PDCs
activation [11]. In addition, an anti-CD303 monoclonal
antibody currently represents the most specific marker
to detect PDCs on tissues sections (Figure 1) [12].
The dichotomous function of PDCs, i.e. production of
type I IFN and DCs differentiation [13], is associated with
distinct morphological and structural changes, as well as a
shift of the transcriptional machinery [14,15]. In particu-
lar, as PDCs differentiate to DCs they lose the capacity to
produce type I IFN and upregulate MHC class I and II and
the T-cell costimulatory molecules CD40, CD80 and CD86
[2,16,17]. PDCs are the major cellular source of type I IFN
(especially IFN-a) [3], which induces a strong antiviral
state [17,18]. The main PDCs pathogen recognition recep-
tors reside in the endosomes and consist of Toll-like recep-
tors (TLR)-7 and -9, whose engagement leads to powerful
type I IFN secretion, followed by DCs differentiation
[15,19,20]. TLR-7 and TLR-9 respond to viral RNA and
DNA that reach endosomes upon cell infection or autop-
hagy [15]. In addition, these receptors can detect self-DNA
in the context of autoimmunity, especially in combination
with proteins (such as the natural antimicrobial peptide
LL37, anti-self DNA antibodies and the High mobility
group box 1/HMGB1 protein), that form complexes with
extracellular self-DNA, preventing its degradation and
promoting the intracellular transport and prolonged
association with endosomes [15,21]. The master mediator
of type I IFN production, occurring downstream of TLR-7/9
signalling, is the transcription factor IRF7, whose consti-
tutive expression by PDCs may also explain their robust
production of this cytokine upon activation [9]. In addition
to BDCA2 and ILT7, other surface receptors (e.g. NKp44,
DCIR) negatively regulate the amplitude of the type I IFN
response by PDCs, while others behave as activators (e.g.
FCgRIIa/CD32 and CD300a/c).
In addition to type I IFN, PDCs produce other cytokines,
including TNF-a IL-6, and CXCL8 [17,22], and inflamma-
tory chemokines such as CXCL9, CXCL10, CCL3, CCL4,
and CCL5 [20,23]. Thus, PDCs influence cells of both
innate and adaptive immune responses [17]. Type I IFNAll rights reserved. doi:10.1016/j.it.2010.05.004 Trends in Immunology 31 (2010) 270–277
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Figure 1. Localization and detection of PDCs in human lymph nodes. (a) PDCs localize in lymph node compartments (filled blue) typically located in areas surrounding B
follicles (B) in the cortex and T nodules (T) in the paracortex. In these areas, PDCs localize in proximity to high endothelial venules (HEV); (SCS: subcapsular sinuses, MC:
medullary cord; MS: medullary sinuses). (b) PDCs are specifically detected in formalin fixed and paraffin embedded tissues using an anti-BDCA2/CD303 monoclonal
antibody (moAb). The figure shows BDCA2-positive PDCs distributed as clusters and dispersed cells; the inset shows a single PDCs within the lumen of a high endothelial
venule. BDCA-2 is not expressed by other cells, and this completely circumvents the issue of specificity encountered when other antigens are targeted. For instance, anti-
CD123 moAb, largely used in the past to stain PDCs in tissue sections, cross-reacts with other cell types, such as endothelial cells, sinus lining cells and activated
macrophages (e.g. epitheliod macrophages in granulomas).
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amplifying type I IFN secretion and inducing a state
refractory to viral infections [16,20]. PDCs-derived type I
IFN also regulates T-cell function including long-term T-
cell survival and memory T-helper 1 polarization, CD8+ T-
cell cytolytic activity and IFN-g production [20]. PDCs also
increase NK cell-mediated cytotoxicity and IFN-g pro-
duction, induce differentiation and maturation of MDCs
and, together with IL-6, induce the differentiation of B
lymphocytes into immunoglobulin-secreting plasma cells.
Finally, inflammatory chemokines can attract activated T
cells to sites of inflammation [20]. Interestingly, it has been
shown that PDCs can induce apoptosis of tumour and
virus-infected cell lines, either directly by secreting TRAIL
(TNF-related apoptosis-inducing ligand) upon activation,
or indirectly via the effect of type I IFN on other cytotoxic
cells [24,25]. PDCs contain abundant granzyme B, but the
role of this enzyme as a cytotoxic molecule remains elusive,
because PDCs, in contrast to other cytotoxic cells, lack the
pore-forming perforin [1,26].
Freshly isolated human PDCs are poor antigen-present-
ing cells, but upon activation by viruses, CpG, IL-3 and
CD40L they acquire full DCs morphology and phenotype,
presenting antigen to CD4+ T cells, and cross-priming of
CD8+ T cells, albeit less efficiently than classical MDCs
[17,27–29]. The DCs features of PDCs in vitro are not
demonstrated easily on tissue PDCs [1], possibly results
from loss of specific PDCs markers (e.g. BDCA-2/CD303)
upon activation and differentiation, or the lack of a com-
plete maturation state by tissue PDCs. More recent data
have shown that PDCs, especially when unstimulated or
alternatively stimulated, or in certain anatomical
locations, act as tolerogenic instead of immunogenic cells.
Thismay occur via differentmechanisms, such as secretion
of granzymeB (GrB) to impair T-cell proliferation [30] or by
production of indoleamine-2,3-dioxygenase (IDO) to
promote regulatory T-cell generation [31,32].
Taken together, these observations indicate that PDCs
are flexible in directing T cell responses and support theidea that PDCs and MDCs are not just quantitatively
different, but complementary, exerting coordinated and
independent control of T cell proliferation and differen-
tiation that may provide fine tuning and plasticity to
immune responses [27,29].
Molecules involved in PDCs trafficking
Pioneering work by Cella and colleagues suggested that
PDCs could migrate directly from the blood compartment
into lymph nodes, across high endothelial venules (HEV)
[3] (Figure 1). This hypothesis was subsequently con-
firmed, in the mouse. Indeed, PDCs express lymph node
homing molecules such as L-selectin and PSGL1, the
counter-ligand of P- and E-selectins [33,34]. In addition,
PDCs express CXCR4, the receptor for CXCL12, which is a
homeostatic chemokine expressed by HEV [3,33,35–37]. L-
selectin and CXCL12 are apparently central in inducing
PDCsmigration, as shown by the reduced number of PDCs
in the secondary lymphoid organs of mice defective for L-
selectin and DOCK2, a molecule involved in CXCR4 sig-
nalling in PDCs [34,38]. CXCL12 may also have a role in
the development of PDCs in bone marrow stromal cell
niches [39]. Under reactive conditions, additional mol-
ecules are involved inmouse PDCs homing to lymph nodes,
such as E-selectin and the chemokine receptors CCR5 and
CXCR3 [36,37,40]. Consistent with in vivo data, mouse
PDCs migrate in vitro in response to CCL3 and CCL5, and
to CXCL9 and CXCL10, the respective CCR5 and CXCR3
ligands. PDCs also express the chemokine receptor CCR9
and migrate to the CCR9 ligand CCL25 to home to the
small intestine [41] (Figure 2).
PDCs purified from human blood express an extensive
profile of chemotactic receptors including the CC chemo-
kine receptors, CXCR3 andCXCR4 [35]. However, with the
exception of CXCR4, these receptors are apparently non-
functional in transwell-based chemotaxis assays
[35,42,43]. Although unable to directly induce PDCs
migration, CXCR3 ligands increase the chemotactic
response to CXCL12 [42,43]. Furthermore, CXCR3 ligands271
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Figure 2. Trafficking properties of circulating PDCs. Blood PDCs constitutively express high levels of L-selectin, CXCR4 and ChemR23. The ligands for these receptors are
expressed by high endothelial venules (HEV); therefore, these molecules may account for the homeostatic recruitment of circulating PDCs to lymph nodes. Under
inflammatory conditions other molecules become involved in this process, such as PSGL-1, the ligand for E-selectin, b1 and b2 integrins and the chemokine receptors CCR5
and CXCR3. CCR7 is upregulated following activation, and is likely to be involved in the migration of mature PDCs through the engagement of its ligands CCL19 and CCL21,
presented by HEV. Under pathological conditions, PDCs are also recruited to peripheral tissues; the molecules involved in this process have not been characterized directly.
However, PDCs are known to migrate in response to chemokines and other chemotactic factors that are produced, or upregulated, during inflammation. In the mouse, CCR9
and its ligand CCL25, are responsible for the recruitment of PDCs to the small intestine both under homeostatic and inflammatory conditions. The different colors indicate
the molecules involved in homeostatic (blue) and inflammatory (red) PDCs trafficking; also, constitutive molecules may be upregulated during inflammatory reactions. In
the blood vessel, adhesion molecules and their respective counter-receptors are indicated in red or blue, chemotactic factors and their receptors in green. Evidence for the
involvement of the different molecules is sometimes related only to mouse or human work; see the text for details and related references.
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migration when immobilized on heparan sulphates
expressed by endothelial cells [33]. Two recent reports
showed that PDCs purified from patients with chronic
hepatitis C, or exposed in vitro to IFN-a, acquire the ability
to respond to CCR2, CCR5 and CXCR3 ligands [44,45].
These results suggest that under appropriate stimulatory
conditions, additional chemokine receptors may be
involved in human PDCs recruitment. In line with this
hypothesis, leukemic PDCs express a wider profile of
functional chemokine receptors than the normal circulat-
ing counterpart [46]. In addition to chemokines, adenosine
and F2L, two agonists released by damaged tissues at the
site of inflammation, have the ability to induce PDCs
migration through the engagement of the adenosine re-
ceptor A1 and FPR3 (the formyl peptide receptor formerly
known as FPRL2), respectively [47,48]. It was also
reported that like MDCs, PDCs have functional receptors
for the anaphylatoxins C3a and C5a [49]. Finally, IL-18
induces the migration of PDCs and promotes the differen-
tiation of Th1 lymphocytes [50]. All these data suggest
that, in addition to chemotactic cytokines, signals associ-
ated with inflammation and tissue damage may contribute
to recruitment of PDCs to pathological tissues.
Recruitment ofPDCs tonon-lymphoid tissues is observed
in certain pathological conditions, such as autoimmune272diseases (i.e. lupus erythematosus disease, psoriasis and
rheumatoidarthritis) [1,51,52], allergicdiseases (i.e. contact
dermatitis and nasal mucosa polyps) [53] and in tumors
[2,54] (Table 1). However, the mechanisms underlying this
effect are elusive. Recently, we and others have character-
ized chemerin, the ligand ofChemR23, as anew chemotactic
factor for PDCs (Box 1) [55,56]. Chemerin is expressed by
HEV in reactive lymph nodes and by activated dermal blood
vessels in autoimmune skin lesions [55,57,58]. Therefore,
current evidence strongly implicates the ChemR23/che-
merin axis in the regulation of human PDCs trafficking to
lymph nodes and to pathological tissues.
Of note, although the migration of blood PDCs to sec-
ondary lymphoid organs and to peripheral tissues has so
far attracted the most attention, there is evidence that
PDCs may also enter lymph nodes via the lymphatic route
[59]; further studies are needed to address this issue in
humans.
Accumulation of PDCs in human diseases: recent
advances
Similar to other human leukocytes, PDCs can undergo
neoplastic transformation (Box 2) and accumulate during
some inflammatory pathological conditions [1,27]. Pathol-
ogists can easily detect human PDCs on archival tissues
using anti-CD303 as a marker and can screen for their
Table 1. Pathological conditions characterized by PDCs tissue infiltration1,12,27.
Disease Tissues
Accumulation of ‘‘pathogenetic’’ PDCs with increased function
Lupus erythematosus Skin and kidney
Lichen planus Skin and mucosa
Psoriasis Skin
Rheumatoid arthritis Synovial tissue
Nasal allergy Nasal mucosa
Accumulation of PDCs with defective function
Melanoma Primary and metastatic tumor site
Carcinomas (ovary, breast, head and neck) Primary tumor site
Accumulation of PDCs with anti-viral/ anti-tumor response
Human Herpes Virus infection Skin
Human Papilloma Virus infection Skin
Molluscum Contagiosum Virus infection Skin
EBV-infection (Hydroa vacciniformis) Skin
Imiquimod-treated carcinomas, melanoma and viral infection Skin
Accumulation of PDCs (function unknown)
Kikuchi’s lymphadenitis Lymph node, skin
Hodgkin’s lymphoma Lymph node
Castleman’s disease, hyalin vascular type Lymph node
Granulomas (infectious, sarcoidosis) Lymph node
Cutaneous Pseudolymphomas Skin
Cutaneous Marginal Zone Lymphomas Skin
Decrease in number/function of PDCs
Human Immunodeficiency Virus infection Peripheral Blood
Hepatitis C Virus infection Peripheral Blood
Solid tumors and haematologic malignancies Peripheral Blood
A wide spectrum of human diseases including infection, cancer and autoimmunity is associated with accumulation of PDCs in lymphoid and peripheral tissues, or reduction of
PDCs in peripheral blood. For many of these diseases, compelling evidence supports a pathogenic role of PDCs accumulation, mainly related to either the increase or the
reduction of PDCs function. Alternatively, PDCs accumulation might exert an adjuvant immune function, as in viral infection, and in Imiquimod-treated cancers. In many other
pathologies, information available is still limited and PDCs function largely unknown.
Box 1. The chemerin/ChemR23 axis in inflammation
ChemR23 is a serpentine Gi-coupled receptor originally cloned by
Parmentier and colleagues [91]. ChemR23 is expressed by antigen-
presenting cells, such as MDCs, PDCs and macrophages, and by
blood monocytes and NK cells [55,58,92]. In contrast to other
chemotactic receptors, human ChemR23 maps to chromosome 12,
and shows little homology with other receptors of the same family
(e.g. 38%, 36% and 35% with C3aR, C5aR and FPR1, respectively). In
vivo, ChemR23 is expressed in the lymph node by interfollicular
MDCs and PDCs, by sinus macrophages and by germinal center
macrophages. In inflamed skin, ChemR23 expression is mostly
restricted to MDCs and PDCs [55]. Chemerin, the only natural ligand
so far identified for this receptor, was originally purified from
ovarian cancer ascites and rheumatoid synovial fluids, and corre-
sponds to the product of the Tig-2 gene. This protein contains a
cystatin fold, and, similar to other family members, it is produced as
an inactive precursor that is activated through proteolytic cleavage
of the C-terminus by proteases released from neutrophils and
proteases generated by the coagulation cascade or produced by
bacteria [93]. In vivo, chemerin is produced by HEV and sparse
perivenular spindle cells in the interfollicular area of the lymph
node, and in inflamed skin, by activated blood endothelial cells,
fibroblasts, and epithelial and mast cells. The anti-inflammatory
lipid Resolvin E1 was shown to exert its function through interaction
with ChemR23. In addition, chemerin proteolytically generated
peptides possess anti-inflammatory activity in vivo [94,95]. There-
fore, ChemR23 may also possess anti-inflammatory activities, as
recently suggested in experiments testing a mouse model of lung
inflammation [96]. CCRL2, an orphan serpentine receptor binds
chemerin at the N-terminal in the absence of receptor signalling and
internalization, and presents chemerin to ChemR23-positive cells in
vitro [56]. This finding discloses a new potential role of chemerin in
leukocyte recruitment. Chemerin was recently shown to be pro-
duced by adipocytes and to act as an autocrine differentiation and
activation factor. Therefore the potential role of chemerin in the
metabolism of adipose tissue represents a new area of active
research [97].
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pathological conditions can be characterized by the pre-
sence of PDCs (Table 1). In this section we summarize
findings for several of these pathologies where abnormal-
ities in PDCs are thought to contribute to disease.
Autoimmune inflammatory dermatoses as a paradigm
of PDCs-associated disease models
PDCs are normally absent from the skin. However, they
accumulate in some inflammatory dermatoses, where they
organize local immune responses [60]. The best character-
ized examples of these conditions are lupus erythematosus
(LE) [61] and psoriasis [62]. Conversely, in other skin
diseases, such as atopic dermatitis, PDCs are not recruited
to the inflamed tissue [53]. In LE and psoriasis, cutaneous
accumulation of PDCs is associated with the local acti-
vation of the chemerin/ChemR23 axis (Box 1) [55,57,63]. In
particular, chemerin is strongly induced in keratinocytes,
dermal vessels and fibroblasts, whereas skin infiltrating
PDCs strongly express ChemR23. The kinetics and distri-
bution of cutaneous PDCs infiltration is different in these
two pathological conditions. In psoriasis, PDCs infiltration
is restricted largely to the dermis, and predominantly
found in early phases of the disease [57,62]. In contrast,
in LE skin lesions PDCs persist during the entire spectrum
of the disease [63] and are located, not only in the dermis,
but also at the dermo-epidermal junction in areas of epi-
thelial cell damage. These findings suggest a novel view of
the role of these cells in skin autoimmunity, where PDCs
might coordinate the dermal immune reaction and sustain
epithelial damage via secretion of cytotoxic molecules. In
fact, cytotoxic damage is a major pathological event in the
‘‘interface’’ dermatitis found in LE, and similar changes,273
Box 2. Tumors derived from PDCs
Proliferation of PDCs in tumors occurs under two distinct clinico-
pathological conditions: one is composed of morphologically
mature PDCs that are barely distinguishable from their normal
counterparts; the other, defined as blastic PDCs neoplasms (BPDCN)
[98], consists of PDCs showing an immature morphology. De novo
expression of antigens such as CD2, CD5 and CD7 has been reported
in both conditions, but a more profound aberrant phenotype is
typically found in BPDCN, with frequent loss of classical PDCs
markers (such as CD68 and GrB) and expression of CD56 and TdT
proteins [12]. Both conditions can be associated with myeloid
neoplasms. In mature PDCs, proliferation is a constant finding [99],
and the myeloid neoplasm is generally represented by chronic
myelomonocytic leukemia. The clonal relationship between PDCs
and myeloid leukaemia is supported by FISH analysis that demon-
strated identical cytogenetic abnormalities in the two cell popula-
tions [99,100]. On the other hand, only ten to twenty per cent of
BPDCN cases are associated with a myeloid neoplasm, generally
consisting of an acute or chronic leukemia with monocytic
differentiation that may be associated with an underlying myelo-
dysplastic syndrome. This myeloid leukemia can precede, coexist or
develop subsequently to BPDCN.
Mature PDCs tumors manifest as nodular accumulations of PDCs,
especially in lymph nodes and bone marrow, while BPDCN typically
presents with multiple skin lesions that rapidly spread to bone
marrow and multiple organs. The peculiar skin tropism of PDCs in
BPDCN has been related to their expression of the neural cell
adhesion molecule CD56 and of the skin homing receptor CLA. In
addition, leukemic PDCs express the chemokine receptors CXCR3,
CXCR4, and CCR7, whose respective ligands CXCL9, CXCL12, and
CCL19 are concomitantly found in cutaneous sweat glands and
follicle epithelium [46].
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PDCs co-localize at the dermo-epidermal junction with NK
cells [58]. These observations point toward a role for PDCs
as effector cells. In all these dermatoses, production of high
levels of type I IFN by PDCs is pathogenic. In LE, type I
IFN is induced in response to nucleic acid-containing
immunocomplexes internalized through Fc receptors. In
psoriasis, a recently reported mechanism of PDCs acti-
vation is based on the production of the endogenous anti-
microbial peptide LL37 by damaged keratinocytes. LL37 is
able to bind and convert self-DNA or self-RNA into potent
TLR-dependent PDCs triggers [64,65]. Remarkably, LL37
is induced strongly in the lesional epidermis of psoriasis
biopsies [66]. Therefore, locally activated PDCs acquire the
ability to release large amounts of type I IFN, that in turn
sustains B and T cell autoimmune responses.
Tumor-associated PDCs: new players in cancer
immunity
Type I IFN plays a prominent role in limiting tumor cell
growth, and several human cancers are treated with type I
IFN [67]. However, the role of PDCs in the control of tumor
cell proliferation is still questionable. In a clinical study,
TLR-dependent activation of PDCs contributed to rejection
of cutaneous tumors. In this condition, PDCs produced
type I IFN, expressed TRAIL and localized together with
T cells and NK cells [25]. Interestingly, a new cell popu-
lation of CD11c+ myeloid DCs endowed with tumoricidal
potential was identified in these lesions [25]. The relevance
of PDCs in cancer immunosurveillance has been recently
shown in mice [68,69], where TLR9-activated PDCs lead to
the regression of subcutaneous B16 melanoma tumors, by274orchestrating the sequential activation of NK cells, MDCs
and CD8+ T cells.
The characterization of PDCs has been performed in a
variety of human neoplasms [54,70–72]. However, the
potential impact of PDCs for cancer immunity is based
largely on in vitro studies of circulating PDCs, while PDCs
detectable at the tumour site (tumor-associated PDCs, TA-
PDCs) are poorly characterized. Available data on TA-
PDCs indicate that they are defective in type I IFN pro-
duction, and secrete indoleamine 2, 3-dioxygenase (IDO)
[73]. It should be noted, however, that the possibility that
PDCs may produce IDO has been questioned [20]. The
production of type I IFN in vitro can be inhibited by cross-
linking surface receptors such as CD303, NKp44 and ILT7
[20]. The identity and tissue source of the natural ligands
for CD303 and NKp44 remain elusive. In contrast, ILT7
ligands, including BSTA2, are expressed by several human
cancer cell lines, and inhibit strongly the production of type
I IFN by activated PDCs [11,74]. A novel mechanism was
proposed recently, where PDCs may exert tolerogenic,
instead of immunogenic, functions. In fact, it was reported
that IL-10 can induce human circulating PDCs to suppress
T-cell proliferation through the secretion of GrB [30]. This
finding is of interest given the high amounts of IL-10
produced in the tumour microenvironment and might
explain the pro-tumorigenic effect of this cytokine observed
in some experimental conditions [75].
In summary, properly activated PDCs are naturally
endowed with anti-tumor activity, but the tumor micro-
environment can subvert this property. There are some
data on the migration mechanisms adopted by TA-PDCs,
with the CXCR4/CXCL12 axis being involved in the
migration to ovarian cancer and melanoma [54,71]. The
availability of new experimental models and new strat-
egies for depleting PDCs in vivo will be extremely helpful
in defining the trafficking properties and the role of PDCs
in tumour growth.
Modulation of leukocyte recruitment by PDCs
The production of chemokines by DCs subsets represents
an important level of immuneregulation [76,77]. As men-
tioned, the potential of PDCs to regulate leukocyte recruit-
ment is mostly related to the ability of these cells to
respond to viral infection with high levels of type I IFN
production. HSV1-activated PDCs recruit T and NK cells
through the production of CXCL9, CXCL10 and CCL4, and
CD40-engagement further strengthens this response
[78,79]. Exposure of PDCs to HIV-1 surface components
triggers the secretion of the CCR5 ligands CCL3 and
CCL4, suggesting a role of PDCs in limiting viral spreading
[80]. In the lung, PDCs are among the earliest inflamma-
tory cells to enter the bronchoalveolar space following
influenza A virus infection [81], and support the recruit-
ment of CXCR3+ and CCR5+ effector T cells through the
local secretion of CXCL10 and CCL5 [82]. A protective role
for C5a in allergic asthma has been linked to a shift in the
MDC/PDCs ratio toward PDCs, with an accompanying
decrease in CCL17 production [83]. Furthermore, PDCs
depletion exacerbates respiratory syncytial virus lung
immunopathology [84]. In indirect acute lung injury, PDCs
are thought to control the recruitment of inflammatory
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[85]. Also,PDCs-inducedCXCL8secretionmight impact the
recruitment of neutrophils into the lung during chronic
obstructive pulmonary disease [86]. PDCs-derived CXCL10
was also shown to be responsible for recruiting CXCR3+ T
cells to cutaneous LE lesions [51], and the cerebrospinal
fluid of patients with neuropsychiatric lupus [87]. In this
context, PDCs have also been implicated in autoimmune
diseases by promoting Th17 immune responses through the
production of IL1b and IL23p19 [88,89]. Moreover, by
secreting CCL4, PDCs might be involved in regulatory T
cell recruitment to the tumor site, representing an
additionalmechanism for controlling immune function [90].
Concluding remarks
More than fifty years since the first description of the
‘‘enigmatic’’ cell population now known as PDCs, many
aspects of PDCs biology still await clarification. The mech-
anisms that govern the in vivo distribution of these cells
under homeostatic conditions remain elusive, and the
biological role of PDCs in many diseases in which they
are regularly detected is poorly understood. Paradoxically,
more information is available on the involvement of PDCs
in human inflammatory and neoplastic conditions than in
experimental models, hampering the correct understand-
ing of the molecular basis of PDCs activation. The new and
more specific reagents now available to detect PDCs in
human and mouse tissues will be instrumental in defining
the role of PDCs in immune responses. Furthermore, the
possibility to generate mice selectively depleted of PDCs
will allow conceptual models about PDCs function to be
probed in vivo. Therefore, it is likely that in the next few
years we will be able to evaluate in a critical manner the
available literature and to advance our current knowledge
on the biological function of PDCs.
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